Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 10, 2015
Reporting Period: Fourth quarter and full year ended December 31, 2014.
This filing serves as a notification that the Company issued a press release regarding its financial results for the period mentioned above. The detailed financial data is contained in the attached press release (Exhibit 99.1) and is incorporated by reference.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus prior periods. It only confirms the issuance of results for the fourth quarter and full year 2014.
Guidance, Outlook, and Risks
- Conference Call: The Company scheduled a conference call for March 11, 2015, at 9:00 a.m. Eastern Time to present financial results. A live webcast was available on the Company's website.
- Forward-Looking Statements: The filing contains forward-looking statements regarding plans, strategies, and intentions. These are subject to risks and uncertainties, including those detailed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013.
- Legal Disclaimer: Information in Item 2.02 is "furnished" and not "filed" under Section 18 of the Exchange Act, limiting liability for these statements.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific revenue, net loss, and cash position figures for Q4 and FY 2014.
- Verify the details of the conference call presentation held on March 11, 2015, for management commentary on the results.
- Consult the Form 10-K for the fiscal year ended December 31, 2013, to understand the specific risk factors referenced in this filing.
- Confirm the Company's cash runway and burn rate, as these are critical for a pharmaceutical company in this stage, though not explicitly stated in this text.